Arcadia Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(2,974) | $(11,133) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | (493) | (5,965) |
| Issuance and offering costs allocated to liability classified options | — | 430 |
| Valuation loss on March 2023 PIPE | — | 6,076 |
| Depreciation | 92 | 227 |
| Lease amortization | 502 | 535 |
| Amortization of note receivable discount | (90) | — |
| Gain on disposal of property and equipment | (65) | (36) |
| Gain on sale of RS durum wheat trait | (4,000) | — |
| Stock-based compensation | 395 | 573 |
| Write-down of inventories | 154 | 444 |
| Impairment of property and equipment | 36 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (445) | 249 |
| Inventories | 620 | (1,388) |
| Prepaid expenses and other current assets | 287 | (284) |
| Other noncurrent assets | — | (13) |
| Accounts payable and accrued expenses | (719) | (300) |
| Amounts due to related parties | (29) | (2) |
| Other current liabilities | (11) | 11 |
| Operating lease liabilities | (678) | (573) |
| Net cash used in operating activities | (7,418) | (11,149) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of property and equipment | 342 | 42 |
| Proceeds from sale of Verdeca — earn-out received | — | 569 |
| Proceeds from sale of investments | 2,501 | — |
| Proceeds from sale of RS durum wheat trait | 4,000 | — |
| Cash paid related to sale of GoodWheat | (2,000) | — |
| Purchases of property and equipment | (16) | (5) |
| Purchases of investments | — | (5,002) |
| Net cash provided by (used in) investing activities | 4,827 | (4,396) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE | — | 5,997 |
| Payments of offering costs relating to March 2023 PIPE | — | (497) |
| Proceeds from ESPP purchases | 9 | 12 |
| Net cash provided by financing activities | 9 | 5,512 |
| Net decrease in cash and cash equivalents | (2,582) | (10,033) |
| Cash and cash equivalents — beginning of period | 6,518 | 20,644 |
| Cash and cash equivalents — end of period | $3,936 | $10,611 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Common stock options issued to placement agent and included in offering costs related to March 2023 PIPE | $— | $212 |
| Warrant and option modifications included in Valuation loss on March 2023 PIPE | $— | $404 |
| Right of use assets obtained in exchange for new operating lease liabilities | $86 | $— |
| Note receivable recognized from sale of GoodWheat | $5,705 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.